Compugen Secures $134.9M Cash Runway Into 2029, COM701 Trial On Track
CGEN•Compugen ended Q1 2026 with $134.9 million in cash and no debt, providing a runway into 2029. Enrollment is active across U.S., Israel and France for the COM701 MAIA-ovarian trial with an interim progression-free survival analysis expected by Q1 2027.
1. First Quarter Financial Results
In Q1 2026, Compugen reported revenues of $2.2 million, a net loss of $7.7 million, and R&D expenses of $6.9 million, up from $5.8 million a year earlier. G&A expenses were $2.3 million, and the company posted a $0.08 loss per share.
2. COM701 MAIA-Ovarian Trial Progress
Enrollment for the MAIA-ovarian Phase 2/3 trial of COM701 is underway at sites in the U.S., Israel and France. The trial targets median progression-free survival at an interim analysis scheduled for Q1 2027, marking a key potential inflection point for the maintenance therapy.
3. Partnered Programs and Data Updates
AstraZeneca is advancing the PD-1/TIGIT bispecific rilvegostomig across 11 Phase 3 trials, with late-breaking Phase 2 data presented in HER2-positive gastric cancer and upcoming data slated for ASCO 2026. The Gilead-partnered GS-0321 Phase 1 trial is progressing according to plan.
4. Strategic Financial Position
Compugen held $134.9 million in cash and equivalents at March 31, 2026, with no debt, supporting operations into 2029. Partnerships with AstraZeneca and Gilead offer up to $1 billion in potential milestones plus royalties, underpinning the immuno-oncology pipeline.
